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The systematic application of next-generation sequencing to large cohorts of oncologic
samples has opened a Pandora’s box full of known and novel genetic lesions implicated
in different steps of cancer development and progression. Narrowing down to B cell
malignancies, many previously unrecognized genes emerged as recurrently mutated.
The challenge now is to determine how the mutation in a given gene affects the
biology of the disease, paving the way to functional genomics studies. Mutations
in NOTCH family members are shared by several disorders of the B series, even if
with variable frequencies and mutational patterns. In silico predictions, revealed that
mutations occurring in NOTCH receptors, despite being qualitatively different, may
have similar effects on protein processing, ultimately leading to enhanced pathway
activation. The discovery of mutations occurring also in downstream players, either
potentiating positive signals or compromising negative regulators, indicates that multiple
mechanisms in neoplastic B cells concur to activate NOTCH pathway. These findings
are supported by results obtained in chronic lymphocytic leukemia and splenic marginal
zone B cell lymphoma where deregulation of NOTCH signaling has been functionally
characterized. The emerging picture confirms that NOTCH signaling is finely tuned in
cell- and microenvironment-dependent ways. In B cell malignancies, it contributes to the
regulation of proliferation, survival and migration. However, deeper biological studies are
needed to pinpoint the contribution of NOTCH in the hierarchy of events driving B cells
transformation, keeping in mind its role in normal B cells development. Because of its
relevance in leukemia and lymphoma biology, the NOTCH pathway might represent an
appealing therapeutic target: the next few years will tell whether this potential will be
fulfilled.
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INTRODUCTION
Mature B cell malignancies originate from B lymphocytes that can transform at virtually
every stage of the differentiation process, depending on the oncogenic events driving
transformation and on accessory stimuli contributing to the accumulation and expansion
of malignant B cells (1). Reliance on a combination of cell-intrinsic and -extrinsic
factors to drive transformation is a shared feature among this clinically and molecularly
heterogeneous group of tumors. In fact, some of the genetic mutations defining these
tumors hit on signaling pathways that render neoplastic B cells independent of the
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environment, by driving proliferative or anti-apoptotic
pathways, while other mutations target molecular components of
microenvironmental signaling networks. The resulting picture is
likely responsible for the profound alterations of the phenotype
and functional responses of the non-neoplastic elements of
the environment that become “tumor-friendly,” including T
lymphocytes and macrophages (2, 3).
NOTCH pathway is one of the most evolutionarily conserved
signaling cascades across species that regulates important cell
fate decisions during embryonic development. Physiologically,
signaling through NOTCH family members operates in a
context-dependent way promoting cell proliferation, cell death
and activating specific differentiation programs (4). In adult
tissues, NOTCH-mediated signals are important regulators in
the maintenance of self-renewal, contributing for example to
myogenesis, neurogenesis and lymphocyte development (5).
Considering its multiple roles in a wide range of processes
and tissues, aberrations resulting in gain or loss of NOTCH
signaling components and functions have been linked to a
variety of disorders including solid cancers (6) and hematological
malignancies (7), where NOTCH can act either as an oncogene or
as a tumor suppressor. In the past decade an increasing number
of reports described recurrent gain-of-function mutations of
NOTCH1 and NOTCH2 in lymphoproliferative disorders of the
B series, including chronic lymphocytic leukemia (CLL), mantle
cell (MCL), splenic marginal zone (SMZL), diffuse large B cell
(DLBCL) and follicular (FL), Burkitt’s (BL) and Hodgkin’s (HL)
lymphomas. Non-mutational mechanisms of NOTCH activation
have also been reported in multiple myeloma (MM) (8, 9).
This review will cover the main aspects of NOTCH
contribution to B cell malignancies, starting from the
mechanisms through which NOTCH signaling drives normal
B lymphocyte development and commitment, in order to
understand how pathway deregulation and genetic aberrations
may influence B cell transformation.
NOTCH PATHWAY COMPONENTS AND
MECHANISMS OF SIGNALING
Mammals express four NOTCH receptors (NOTCH1-4), each
encoded by a different gene, that interact with five different
ligands (DLL1,-3,-4 belonging to the Delta-like family and
Jagged1 and−2 which are part of the Serrate family of
ligands) (10) (Figure 1). NOTCH receptors are single-pass type
I transmembrane proteins showing high structure homology
(especially NOTCH1 and NOTCH2) and displaying both
common and unique functions. They are synthesized as single
precursors that maturate in the Golgi apparatus upon proteolytic
cleavage (S1) by a furin-like convertase. Mature receptors
expressed on the cell surface are heterodimers composed by anN-
terminal extracellular region (EC) non-covalently associated with
a transmembrane (TM) domain and a C-terminal intracellular
(IC) subunit (11). The EC portion of NOTCH receptors contains
a series of epidermal growth factor (EGF)-like repeats (29–36),
some of which are crucial in mediating ligand interactions
and responses (12). Within the EC domain, the EGF-like
repeats are followed by a juxtamembrane negative regulatory
region (NRR), which contains three Lin12/Notch repeats (LNRs)
and a heterdimerization domain (HD), and which prevents
NOTCH activation in the absence of ligands. The IC portion
of the receptors consists in a protein-binding RBPJk-associated
molecule (RAM), seven ankyrin repeats, and less conserved
regions including a transcriptional activation domain (TAD)
and a C-terminal region rich in proline, glutamate, serine and
threonine (PEST domain), which regulates protein stability and
degradation as it contains the substrate site that is recognized
by E3 ubiquitin ligases (degron domain) (10, 13). Among family
members, NOTCH1 and –2 are the most widely expressed
receptors, being present in many tissues at the developmental
stage, as well as in adults, while NOTCH3 is found mainly in
vascular smooth muscle and pericytes, and NOTCH4 is most
highly expressed in endothelium (6).
NOTCH ligands are also type I TM proteins showing
high structural homology within the Delta-like and Serrate
families, but their expression patterns are less well characterized
than those of the receptors (4) (Figure 1). The strength
and outcome of receptor-ligand interactions are modulated
by post-translational modifications of NOTCH receptors. The
EGF repeats of NOTCH EC region can be modified by the
addition of O-fucose and O-glucose residues, which can in
turn lead to further modifications (14). The addition of O-
fucose by protein O-fucosyltransferase 1 (Pofut1) is required for
subsequent glycosylation of NOTCH receptors by the Fringe
family of glycosyltransferases (Lunatic, Manic and Radical
Fringe). Glycolsylation potentiates the interactions of NOTCH
receptors with DLLs, while reducing responsiveness to JAGs (15).
Binding of NOTCH to a ligand on neighboring cells leads
to a conformational change of the receptor and rescues the
inhibition imposed by the NRR, exposing a cleavage site (S2) for
ADAMmetalloproteases close to the TM domain (16) (Figure 2).
ADAM-mediated cleavage releases the TM-IC regions from the
EC portion of the receptor and this effect is facilitated by,
and partly depends on, a mechanical force delivered to the
receptor by the signal-sending cell through ligand endocytosis
(17). S2 cleavage generates a short-lived membrane-bound form
of NOTCH (NEXT, NOTCH extracellular truncated) that is
rapidly further cleaved by the γ-secretase complex (S3), releasing
NOTCH IC domain (NICD) from the membrane and allowing
its translocation to the nucleus (18, 19). Once in the nucleus,
the NICD forms a transcriptional complex, having RBPJk as
core DNA-binding factor. By binding the transcription factor,
NICD alters the composition of RBPJk-tethered complexes,
shifting the composition from that of a repressor to an activator
of transcription. Specifically, NICD displaces co-repressor
molecules bound to RBPJk, such as HDACs, SHARP, MINT
and SPEN (11, 20–22) and recruits transcription co-activators
of the Mastermind-like family [MAML, (23)], as well as the
histone acetyl transferase p300 (24) and the histone demethylase
KDM1A [also known as LSD1, (25)], to initiate transcription
of NOTCH target genes. Major NOTCH target genes include
the basic helix-loop-helic (bHLH) class of transcription factors,
such as HES1 and HEY1 (26), which act as repressor of
transcription playing critical roles in developmental processes,
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FIGURE 1 | NOTCH receptors and ligands. NOTCH receptors are structurally conserved type I proteins. There are four mammalian NOTCH receptors (NOTCH1-4)
that contain multiple extracellular epidermal growth factor (EGF) repeats (from 29 to 36). Specific EGF repeats mediate ligand interactions. EGF repeats are followed
by the negative regulatory region (NRR), which is composed of three cysteine-rich Lin repeats (LNR) and a heterodimerization domain (HD). NOTCH also contains a
transmembrane domain (TM), an RBPJk associated module (RAM) domain, a nuclear localization sequences (NLS), a seven ankyrin repeats (ANK) domain, a NOTCH
cytokine response (NCR) region, a transactivation domain (TAD) and a proline-glutamic acid-serine-threonin rich (PEST) domain. Mammalian NOTCH proteins are
cleaved by furin-type convertases, which convert the NOTCH polypeptide into a NOTCH extracellular domain (NECD) and NOTCH intracellular domain (NICD)
heterodimer that is connected by non-covalent interactions. After ligand binding, NOTCH is cleaved by metalloproteases and γ-secretase (S1, S2, and S3). NOTCH
ligands can be divided into Jagged (Jagged 1 and Jagged 2) and Delta-like (DLL1, DLL3, and DLL4) groups on the basis of their domain composition. The
extracellular domain of ligands is characterized by a NOTCH ligand N-terminal domain (MNNL), a Delta/Serrate/LAG-2 (DSL) domain, EGF motifs and a cysteine-rich
(Cys) domain. DLLs lack this latter domain. The intracellular portion may contain a post-synaptic density protein ligand domain (PDZL).
as well as in transformed cells. Furthermore, NOTCH activity
fosters a self-regulating feedback loop by transcriptionally
controlling genes encoding cytoplasmic protein that modulate
NICD translocation to the nucleus or binding to RBPJk, such as
Deltex1 (DTX1) and NRARP (27, 28). Among the genes under
a direct NOTCH-dependent transcriptional control, MYC is an
important mediator of NOTCH effects in the transformation
process for several tumor types.
Activity of NOTCH signaling is then terminated through
the phosphorylation of the PEST domain by cyclin C/cyclin-
dependent kinase 8 (CDK) 8 and the subsequent ubiquitinylation
by the E3 ligase complex, containing the F-box protein
FBW7, which drives NICD to proteasome-mediated degradation
(29–31) (Figure 2).
NOTCH SIGNALING PARTICIPATES IN B
CELL DEVELOPMENT
In the study of normal immune system, the role of NOTCH
has been mostly characterized in T cell development, where it
regulates T cell commitment of common lymphoid progenitors
(CLPs) at the expenses of B cell differentiation (32). B
lymphopoiesis takes place in the bone marrow (BM) where newly
formed B cells are generated from CLPs, before branching into
a B1 subset or continuing toward pro-B cells. The former gives
rise to long-lived lymphocytes, predominantly found during fetal
and neonatal life, and residing in the peritoneal and pleural
cavities in adults, where they complete their differentiation
into IgM-producing plasma cells (33). On the contrary, pro-B
cells differentiate to immature B lymphocytes that migrate to
the spleen as transitional type 1 (T1) B cells, then developing
into type 2 transitional B cells (T2). T2 lymphocytes can
further differentiate in mature B2 cells, which represent the
predominant B population in adult secondary lymphoid organs
and the main effectors of adaptive immunity. Following specific
microenvironmental signals, they differentiate in two main
subsets in a T cell-independent or -dependent way, respectively:
(i) marginal zone (MZ) B lymphocytes, residing exclusively in the
spleen, and (ii) follicular (FO) B cells that can circulate and are
more widely distributed in splenic and lymph node (LN) follicles,
as well as in the BM, and can participate in germinal center (GC)
reaction (34).
The expression and functions of NOTCH components in
normal B cell biology has so far proven controversial for many
aspects, likely because these proteins show distinct roles in early
vs. late phases of B cell development and when considering
fetal or adult B cell generation. For instance, in a study
performed on human fetal B cells, Bertrand and colleagues
showed that NOTCH1 mRNA and proteins are expressed,
throughout normal B cell development, whereas NOTCH2
expression is limited to late pre-B cells expressing low levels
of surface immunoglobulin. The authors hypothesized that,
given its ubiquitous expression in B cell development, NOTCH1
could modulate proliferation and B cell differentiation through
multiple developmental checkpoints (35). In contrast to these
observations, other studies examining adult murine B cell
subsets, described amodulation of NOTCH components through
B cell development, with NOTCH1 and NOTCH3 being highly
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FIGURE 2 | NOTCH signaling pathway. Ligand expressed on the surface of the signal-sending cell binds to NOTCH expressed on the surface of the signal-receiving
cell and induces sequential cleavages by A-Disintengrin-And-Metalloprotease (ADAM) and γ-secretase, ultimately releasing the NOTCH intracellular domain (NICD)
from the membrane. NICD translocates to the nucleus where it mediates the displacement of co-repressors (CoR) and Histone DeAcetylase Complex (HDAC) and
directly interacts with RBPJk recruiting co-activators (CoAct), finally inducing target gene transcription. The signaling pathway is shut down by phosphorylation of the
NICD subunit by C/Cyclin-dependent kinase 8 (CDK8) and subsequently poly-ubiquitinated by F-box containing protein (FBW7) and degraded via proteasome. The
strength and outcome of receptor-ligand binding can be modulated by post-translational modifications of NOTCH receptors, operated by the Fringe family of enzymes.
expressed in pro-B cells, progressively decreasing in pre- and
immature B cells and maintaining low levels in peripheral B cells.
At variance, NOTCH2 transcript was progressively upregulated
with sustained expression in peripheral B cells (36).
Ligands belonging to both DLL and Jagged families are
expressed on the surface of a wide range of BM stromal
cells and can exert different effects on signal-receiving cells
depending on the differentiation status of B cell progenitors
and the cooperation with accessory stimuli present in the
niches (37). Importantly, their expression is discontinuous,
turning NOTCH signaling on or off according to developmental
needs. B cell development is driven by specific cytokines such
as CXCL12 in the earliest phases and interleukin (IL)-7 as
differentiation proceeds (38). Early B cell progenitors such as pre-
pro B cells reside in microenvironmental niches where CXCL12
is expressed, while NOTCH ligands are not. In fact, CLPs
commitment to the B cell lineage requires NOTCH signaling
shut down, at variance with T cell development, which is
strictly dependent on NOTCH1 expression (39). As development
proceeds, B cell precursors migrate from CXCL12- to IL-7-
expressing stroma, an environment where both DLL and Jagged
ligands are expressed, suggesting that NOTCH signaling may
have a role in committed B cells developing in the BM and ready
to migrate toward secondary lymphoid niches to complete the
differentiation process (37, 40).
Furthermore, beside BM stroma, developing B cells can
themselves surface express NOTCH ligands, thereby suggesting
that NOTCH signaling can operate through multiple cellular
interactions, other than stromal cells. Indeed, Bertrand and
colleagues observed that Jagged-1 is mainly expressed by BM
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stromal cells whereas Delta-like ligands are preferentially
expressed in pro-B and pre-B cells, hypothesizing different
outcomes of NOTCH signaling according to different ligand
binding. They suggested that NOTCH-DLL interactions
occurring between B cell precursors with equivalent
developmental potential (termed “lateral signaling”), may
contribute to the maintenance of a normal B lineage homeostasis,
by signaling some cells to commit to a specific differentiation
fate, while maintaining others in the original precursor state
(35).
While the impact of NOTCH signaling in early B
cell development is still controversial and only partially
clarified, its role later on in the differentiation process is
better documented. For example, conditional knock out of
NOTCH2 in murine B cells results in the complete absence
of MZ B cells, without affecting other B cell subsets, and in
increased mortality due to blood-borne bacterial infections
(36, 41). Expression of NOTCH2 is thus essential to drive B
cells toward MZ maturation. Furthermore, NOTCH ligands
show partially overlapping expression patterns in the spleen,
with preferential association with vascular stromal cells.
Specifically, stromal cells within the MZ strongly express
DLL1, which is needed for complete MZ B cell development
(42, 43).
Together with MZ cells, B1 lymphocytes are considered
innate-like lymphocytes showing an antibody repertoire
to recognize pathogen-associated molecular patterns. B1
cells can originate from early lymphoid progenitors and
CLPs but not from pro-B cells, indicating that cell fate
of B progenitors becomes restricted as soon as cells show
commitment toward a specific B lineage (44). Similar to B2
MZ differentiation, NOTCH2 signaling takes part in B1 cells
development and maintenance. As shown in a study by Witt
and colleagues, NOTCH2 haploinsufficiency resulted in reduced
B1 B cells in the peritoneal cavity compared to wild-type
mice (45). Interestingly, the same group also showed that,
at variance with NOTCH1 activation in CLPs that drives T
cell commitment, ectopic induction of NOTCH2 signaling,
obtained by transducing BM cells with the activated intracellular
domain of NOTCH2 (ICN2), boosted early B cell development
and B1 commitment while blocking B2 progression at the
pre-B stage (46). These observations suggest that, despite
the strong similarities in signaling components, activation
of NOTCH pathway plays a critical role in lymphocyte
development showing distinct non-redundant functions
(Figure 3).
Finally, NOTCH signaling also contributes to B cell activation
and terminal differentiation to antibody-secreting cells (ASCs)
by acting synergistically with B cell receptor (BCR) pathway and
co-stimulatory signals such as CD40 or BAFF. The outcome for
B cells is increased cell survival and proliferation, along with
activation and antibody production (47, 48).
Given the multiple implications of NOTCH signaling in B
cell development, it is perhaps not surprising that alterations
of pathway activity are associated with B cell malignancies. The
following paragraphs of this review will focus on the deregulation
of NOTCH pathway in various models of B cell neoplasia,
starting from chronic lymphocytic leukemia where the biological
meaning of this pathway in the pathophysiology of the disease is
better characterized than in other B cell malignancies.
NOTCH1 IS ABERRANTLY ACTIVATED IN
CHRONIC LYMPHOCYTIC LEUKEMIA
(CLL)
Among B cell malignancies, CLL represents the most frequent
adult leukemia with an incidence rate of ∼3.9/100,000/year (49).
It is characterized by the progressive accumulation of mature-
looking CD5+/CD23+ B lymphocytes in the peripheral blood
(PB) with infiltration of lymphoid tissues such as spleen and LNs
(50). Clinically, disease course is highly heterogeneous in terms
of presentation, outcome and therapy responses, with patients
either showing an indolent disease with a limited impact on life
expectancy or exhibiting a rapidly progressive disease despite
early treatment initiation.
To simplify, this largely depends on the B cell precursor
CLL originates from, which is driven by antigen-mediated
triggering of BCR together with multiple accessory signals,
provided by cell-bound and soluble factors, that reinforce
survival and proliferative advantage of leukemic cells (51, 52).
Among others, CLL cells show overexpression and aberrant
activation of NOTCH1 (53, 54), and this is markedly evident
in lymphoid niches (55), likely due to the fact that stromal
cells in the BM and in LNs strongly express NOTCH ligands
(56, 57). Leukemic cells themselves express NOTCH ligands on
the surface, suggesting the existence of autologous signaling (57).
Increased activity of NOTCH1 pathway protects leukemic cells
from apoptosis through multiple mechanisms, among which the
crosstalk with NF-κB signaling represents a key feature in CLL
biology, as it directly regulates expression of anti-apoptotic genes
(e.g., c-IAP2 and XIAP) and surface molecules (e.g., CD49d)
that facilitate interactions with microenvironment, feeding a pro-
leukemic loop (58) (Figure 4). Moreover, NOTCH1 promotes
CLL cell growth and active proliferation by upregulating
genes related to ribosome biogenesis and protein translation
such as NPM1 and ribosomal proteins (RNPs) (59). Even
if a formal demonstration is still missing, these effects are
likely mediated through the up-regulation of MYC, as also
supported by the involvement of a NOTCH1-MYC axis in the
glycolytic switch induced in CLL cells by stromal cells, an event
contributing to stroma-mediated chemoresistance (60). Finally,
NOTCH1 transcriptional activity in CLL upregulates genes
insisting on BCR and cytokine/chemokine signaling, therefore
further sustaining leukemic cell survival and proliferation
possibly amplifying BCR-mediated effects through a synergistic
cooperation (48, 54) (Figure 4).
A further indication underlining the importance of NOTCH1
signaling in CLL comes from the finding that mutations in this
gene have emerged as one of the most frequent single gene
alterations found in CLL at diagnosis (5–15% of cases) (61).
Prevalence increases to∼20%when considering chemorefractory
patients, and up to ∼30% in CLL transforming to aggressive
lymphoma (Richter Syndrome, discussed below) (62). The
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FIGURE 3 | NOTCH signaling in B cell development. In bone marrow-residing CLPs, NOTCH1 signaling must be switched off to allow proper B cell development. On
the contrary, after migration of immature B cells to the spleen, interaction of DLL1 with NOTCH2, with the involvement of recombinant signal binding protein for
immunoglobulin kJ region (RBPJk), induces NOTCH signaling in transitional B (T2) cells to specify marginal zone B cells, as opposed to follicular B cells. NOTCH2
signaling is also necessary for CLPs to differentiate toward B1 cells.
majority of NOTCH1 mutations in CLL occurs within the last
exon of the gene and affects the C-terminal portion of the
receptor. Specifically, the mutation accounting for ∼80% of
cases is a 2-bp deletion in exon 34 that shifts the reading
frame (c7541_7542delCT) and generates a premature stop codon
(P2514fs∗4), truncating the PEST domain (61–63). Frameshift
mutations affecting different nucleotides in exon 34 (64), as
well as mutations in the non-coding 3
′
untranslated region (3
′
-
UTR) of NOTCH1, favoring alternative splicing events with a
cryptic donor site in exon 34 (65), have also been described
with similar effects on the protein. Mechanistically, PEST domain
truncation leads to the loss of the degron domains that direct
NOTCH1 to proteasomal degradation, therefore affecting the
physiological turnover of NICD, increasing its stability and
prolonging pathway activity (66). At variance with T-ALL
where mutations in NOTCH1 HD facilitate ligand-independent
activation (67), triggering of NOTCH1 signaling in CLL strictly
relies on the interaction with the ligand(s), even in the presence
of PEST mutations, as these lesions result in the stabilization of
ligand-triggered cleaved NOTCH1 rather than in autonomous
signaling activation (57).
Clinically, NOTCH1 mutations identify patients with a worse
prognosis in terms of therapy responses and with higher risk
of disease transformation into an aggressive lymphoma (68).
NOTCH1-mutated samples are enriched in chemorefractory
CLL and in vitro evidence shows a marked resistance to
fludarabine-induced apoptosis, which can be rescued by
NOTCH1 inhibitors (57, 69). More recently, an association
between NOTCH1 mutations and reduced benefits from anti-
CD20-based chemoimmunotherapy regimens was described
(70), likely as a consequence of downmodulation of surface
CD20 in this patient subset compared to WT samples (71).
From the biological standpoint, reduced CD20 expression is
due to the fact that accumulation of mutated NICD in the
nucleus perturbs a delicate balance between nuclear interactors,
ultimately impacting on the amount of free HDAC that can
bind to and silence other genomic regions, including the CD20
promoter (71). Understanding this mechanism prompted the
idea that NOTCH1 may exert its effects not only through a direct
transcriptional regulation of gene expression, but also indirectly,
by altering epigenetic regulation. We recently demonstrated that
NOTCH1-mutated cells have an increased migratory potential
in response to chemokines that regulate homing of CLL cells to
lymphoid niches, such as CCL19, because of a higher expression
of the chemokine receptor CCR7. The underlying mechanism
is that free HDAC, displaced from the RBPJk-tethered complex
by an excess of NICD, can interact with and stabilize DNMT3A,
which in turn suppresses the expression of the tumor suppressor
gene DUSP22. Loss of DUSP22 phosphatase activity leads to
aberrant activation of MAPK and STAT3 signaling, both crucial
in CLL homeostasis as downstream players of growth and
chemokine receptors, and consequently to a STAT3-dependent
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FIGURE 4 | NOTCH1 transcriptional effects in CLL cells. NOTCH1 signaling is aberrantly activated in CLL cells, resulting in transcriptional regulation of several genes,
in turn impacting different biological aspects of the neoplastic cells. Increased NOTCH1 activity contributes to leukemic cell growth, protection from apoptosis,
metabolic switching toward a glycolytic metabolism, increased migration in response to specific chemokines and facilitates interactions with microenvironment.
Moreover, it upregulates several genes encoding proteins insisting on the BCR signaling pathway, the driving force for CLL cells.
upregulation of CCR7 expression and responsiveness (66).
Conceivably, NOTCH1-mutated CLL cells may be more prone
to reach privileged lymphoid niches that provide pro-leukemic
stimuli including NOTCH1 ligands, thereby further fueling
pathway activation.
At diagnosis, NOTCH1 mutations can be found either as
a clonal defect, present in the large majority of leukemic
population, or at the subclonal level (cut-off of Variance Allele
Frequency <12%), suggesting that they might be acquired at
different steps during CLL development. Specifically, clonally
represented mutations are indicative of an early event, whereas
subclonal mutations are thought to be acquired later and to be
progressively selected. In favor of the view that the acquisition of
NOTCH1 mutations is a relatively late event, is the observation
that they might be subsequent to at least one driver alteration
such as a chromosomal aberration. Accordingly, NOTCH1
mutations are strongly associated with trisomy 12 (72). On the
other hand, NOTCH1 mutated subclones have been detected
in high-count monoclonal B lymphocytosis (MBL), considered
a pre-malignant state potentially evolving to CLL (73, 74). In
line with the idea that NOTCH1 alterations may be involved in
CLL initiation, several papers revealed the presence of NOTCH1
mutations in early hematopoietic progenitors of CLL patients
harboring the defect at the time of disease presentation (75,
76). From the clinical standpoint, the prognostic impact of a
low NOTCH1 mutated burden, as well as the evolution of the
mutated CLL clone during disease progression, remains unclear.
Some studies reported that subclonal NOTCH1 mutations are
not associated with chemorefractory disease and remain stable
through the follow-up of the disease, suggesting that they
may not confer growth advantage to leukemic cells over WT
cells, thereby not being prognosticators of aggressive/progressive
CLL (77, 78). In contrast, other groups observed that CLL
patients harboring NOTCH1 mutations in a small portion of
the leukemic population show a shorter time to first treatment
and reduced overall survival similar to that of clonally mutated
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CLL (72, 79). Discrepancies in clinical observations may be due
to differences in the cohorts under examination. In the sample
cohort investigated by Rasi and colleagues, NOTCH1 mutations
were mainly present already at the clonal level, with only few
patients showing a mutated fraction below the limit of Sanger
sensitivity, likely not fully recapitulating the dynamics of disease
evolution in which subclonal NOTCH1 mutations might be
implicated (78).
Independently of whether aberrant NOTCH1 signaling is the
result of genetic alterations or of a permissive environment, this
pathway plays a critical role in CLL pathogenesis and progression
and could represent a suitable therapeutic target.
DEREGULATED NOTCHs IN MATURE B
CELL MALIGNANCIES OTHER THAN CLL
A role for NOTCH in tumor development, progression, and drug
resistance has also been highlighted in B cell malignancies other
than CLL. For example, NOTCH deregulation was described in
HL, BL (80, 81), DLBCL (82, 83), and MM (84, 85) (Figure 5).
For most of them, the current knowledge derives from the
massive unbiased sequencing approaches on large cohorts of
samples that highlighted recurrent mutations in genes of the
NOTCH pathway, sharing mechanistic effects on the protein and
pathway activity. MM represents an exception, as deregulation
of NOTCH relies mostly on the overexpression of signaling
components. Overall, form the functional standpoint, the role
of NOTCH alterations in these B cell malignancies is less well
characterized than in CLL. The following sections of this review
are intended to explore the expression, genetics and role of
NOTCH family members in these diseases.
Mantle Cell Lymphoma (MCL)
MCL is an aggressive mature CD5+/CD23− B cell malignancy,
arising from naïve pre-germinal center B cells of the inner mantle
zone and accounting for 6–7% of non-Hodgkin lymphomas
(86). The clinical history is highly variable and ranges from
indolent forms to a very aggressive disease with a short
median survival, frequent relapses and increasing resistance
to chemotherapy (87, 88). Regarding the pathogenesis, the
primary alteration in MCL is the translocation t(11;14)(q13;q32),
that leads to the juxtaposition of the CCDN1 gene with
the IGH locus, resulting in cyclin D1 overexpression and
constitutive activation with consequent cell cycle deregulation
(89, 90). Beside this lesion, secondary genetic alterations are
needed to induce lymphomagenesis by disrupting additional
critical pathways. Several papers described alterations involving
CDKN2A, CDKN2B, TP53, RB1 resulting in deregulation of
MCL cell proliferation (89–92). In order to further understand
the biology of MCL, discover novel pathogenic lesions and
potentially identify novel targets for therapy, Kridel and
colleagues exploited a powerful whole transcriptome shotgun
sequencing (RNAseq) approach applied to primary samples and
cell lines (93). Along with mutations in genes known to be
involved in MCL pathogenesis, they found recurrent mutations
in NOTCH1 (12% for primary samples and 20% in cell lines),
the majority located in exon 34 that encodes the PEST domain,
and thus resulting in an abnormally over-activation of NOTCH1
signaling pathway. Themutational pattern (non-sense truncating
mutations and small frame-shift indels) and frequency were
similar to what described in CLL (61, 62). Mutations inNOTCH1
were associated with a shorter overall survival, suggesting a
negative prognostic role for NOTCH1 in MCL. Functionally,
Kridel and colleagues found that MCL cell lines were sensitive
to NOTCH1 inhibition, as indicated by reduced proliferation
and induction of apoptosis, as well as by the modulation of a
specific gene expression profile (93). In line with these findings,
it was recently demonstrated that NOTCH signaling regulates,
directly or indirectly through MYC, a gene signature insisting on
BCR signaling, RNA metabolism, and chromatin/transcriptional
regulation, thus providing a potential basis for the selective
drive of NOTCH gain-of-function mutations in MCL (94).
These results have broad implications in B cell lymphomagenesis
and pave the way for developing novel therapeutic strategies
involving the use of NOTCH pathway inhibitors in these cancers.
By using whole-genome and whole-exome sequencing
analysis applied to a large cohort of MCL patients, Bea and
colleagues reported that also NOTCH2 mutations are present as
an alternative and mutually exclusive phenomenon to NOTCH1
alterations in aggressive tumors with a poor prognosis (95).
The mutation pattern is similar to that reported for NOTCH1,
with the generation of a premature stop codon within the PEST
domain. Accordingly, gene expression analysis highlighted a
different profile, with NOTCH2 mutated cases displaying an
up-regulation of genes involved in cell-cycle and metabolic
pathways, together with genes directly regulated by NOTCH2
(95).
Follicular (FL), Hodgkin’s (HL), and Burkitt’s
(BL) Lymphomas
Mature follicular B cells represent the pool of recirculating
peripheral lymphocytes that generate both plasmablasts and
memory cells in response to pathogens. FL arises from germinal
center B cells blocked in their capacity to differentiate further
(96, 97). FL is the most common indolent and slowly progressive
lymphoma, with a median survival of 10–14 years (98, 99).
Histologic transformation to an aggressive lymphoma occurs in
2–3% of patients/year and it is associated with chemoresistance,
progression and increased mortality (100). From the molecular
standpoint, FLs are almost universally characterized by the
t(14;18)(q32;q21) translocation which leads to a fusion of BLC2
to regulatory elements of the IGH locus (101). The resulting
constitutive overexpression of BCL2 abrogates the default
germinal center apoptosis, likely representing an initiating
oncogenic “hit.” In addition, the use of high-throughput
sequencing technologies has been helpful in identifying other
recurrently mutated genes that drive transformations (102).
They belong to the BCR/NF-κB signaling, apoptosis, chromatin
remodeling and B cell development pathways (103–108). Most of
them have been functionally validated exploiting mouse models,
confirming their pathophysiological role in FL and leading to
the development of a new wave of drugs (109–112). Recently,
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FIGURE 5 | Mature B cell malignancies classification according to their normal counterpart and overview of NOTCH implications in these disorders. After antigen
contact, naïve B cells are activated and enter the germinal centers. Maturation through a T cell dependent process leads to centroblast differentiation in the dark zone
with high proliferation rate and somatic mutations of immunoglobulin variable regions and continue their maturation through the light zone. After that, they can become
memory B cells or terminally differentiated plasmacells. On the contrary, transitional B cells are selected into a mature B cell repertoire in a T cell-independent way
through the marginal zone of the spleen. B cell malignancies can arise from B lymphocytes at each maturation step. NOTCH family members have been identified as
recurrently mutated in some of these disorders or to be over-expressed, ultimately resulting in an aberrant activation of the pathway.UM-CLL, IGVH unmutated chronic
lymphocytic leukemia; M-CLL, mutated chronic lymphocytic leukemia; FL, follicular lymphoma; HL, Hodgkin’s lymphoma; BL, Burkitt’s lymphoma; DLBCL, diffuse
large B cell lymphoma; MCL, mantle cell lymphoma; MZL, marginal zone lymphoma; MM, multiple myeloma; GC, germinal center.
by analyzing a cohort of 112 FL cases by Sanger sequencing,
Karube and colleagues reported mutations also in NOTCH1 and
NOTCH2. For the former gene, the only detected mutation was
the p.P2514fs∗4, with no alterations in the heterodimerization
domain. For NOTCH2, a nonsense (p.R2400∗) and a frameshift
(p.I2304fs∗9) mutations were reported (113), resembling the
profile found in SMZL (114). All these mutations lead to the
truncation of the PEST domain and thus to a persistently active
NICD, in line with mechanisms described for other B cell
malignancies. Similar results, both in terms of frequency and
pattern of mutations, were confirmed in an independent cohort
by Krysiak and colleagues (115). These authors found novel
mutations in NOTCH3 (4.8%) and NOTCH4 (4.2%), as well as in
the NOTCH signaling regulatorsDTX1 (5.7%) and SPEN (2.9%).
The finding that genes encoding NOTCH components are
altered in subgroups of FLs is in apparent contrast with the
physiological role that NOTCHplays in promotingmaturation of
B cells to MZ (see also Figure 3) (36, 41, 116, 117). On the other
hand, a recent paper pointed out that NOTCH2 downmodulation
is essential for FL cell survival, calling back into question the
significance of NOTCH signaling in this disease (118), and
suggesting that more work is needed to solve this apparent
controversy.
Overall, these findings highlight the NOTCH pathway as
heavily mutated in this disease, but leave open its functional role.
Overactivation of NOTCH signaling pathway has been
reported also in Hodgkin’s and Burkitt’s lymphomas, both
deriving from germinal center B cells. In the former case, tumor
cells are characterized by a higher expression of NOTCH1,
NOTCH2 and Jagged2, but also of Mastermind-like 2 (MAML2),
an essential NOTCH co-activator (119). The final result is an
over-activation of NOTCH signaling pathway as an alternative
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mechanism to the cell-autonomous NOTCH activity, typical of
these cancer cells, as shown by the gene-expression profile studies
(120). The critical role played by this pathway is underlined by the
evidence that targeting of MAML proteins resulted in inhibition
of NOTCH and in a reduced proliferation and growth of HL
cells (119). It has also been reported that NOTCH activation
can trigger NF-kB signaling, promoting survival of HL cells in
cooperation with the Epstein-Barr virus (EBV) (121).
A synergistic mechanism between NOTCH and another
partner has been suggested also in BL, where the counterpart
is represented by the BCR, with c-myc as potential point
of convergence. This cross-talk results in the modulation of
proliferation and apoptosis of lymphoma cells and can be
reverted by using a gamma-secretase inhibitor (80). More
recently, Cao and colleagues, highlighted that specific elements
present in the vascular niche contribute to the modulation of
NOTCH ligand expression, specifically Jagged1, on endothelial
cells that in turns activates NOTCH2 signaling in BL cells,
enforcing their aggressiveness in terms of extra-nodal invasion
and chemoresistance (122).
Diffuse Large B Cell Lymphoma (DLBCL)
and Richter Syndrome (RS)
DLBCL is a highly heterogeneous neoplasm category (123),
accounting for 30–40% of newly diagnosed non-Hodgkin
lymphomas (NHL) (124).
Historically, DLBCL was thought to involve recurrent
translocations of the IGH gene and the deregulation of
rearranged oncogenes, including BCL2, BCL6, or MYC.
More recently, the molecular heterogeneity of DLBCLs has
been deciphered by gene expression profiling, allowing the
classification into two main molecular subtypes: the germinal
center B cell like (GCB) and the activated B cell like (ABC).
These subtypes arise from distinct B cells at separate stages of
differentiation and maturation (125), leading to well-defined
gene expression profiles and different clinical outcomes and
responses to immunochemotherapy, with ABC type being the
most aggressive and characterized by a poor clinical outcome
(126, 127).
The most frequently (≥10% of all samples) mutated genes in
DLBCL belong to pathways controlling cell cycle, DNA damage
response, chromatin remodeling, BCR and TLR signaling (125,
128–133) Additional genes were found to be mutated in a
lower percentage of samples, but potentially relevant to DLBCL
biology, including genes belonging to the NOTCH family.
Very recently, a comprehensive analysis of 304 primary
DLBCLs samples integrated low-frequency alterations, recurrent
mutations, somatic copy number alterations, and structural
variants, to identify five groups of patients with outcome-
associated coordinated genetic signatures, three of which
previously undescribed. PEST mutations in NOTCH2 and
truncating alterations of its negative regulator SPEN, together
with BCL6 structural variants and mutations of the NF-
kB pathway were associated to the Cluster 1 (C1) DLBCLs.
This subset is characterized by an increased transcriptional
abundance of NOTCH2 and BCL6 target genes, as highlighted
by gene set enrichment analysis (GSEA). The majority of C1
DLBCL were classified as ABC-type tumors, by transcriptional
profiling. This novel classification may help tailor treatment
strategies in these genetically distinct DLBCL subsets (134,
135). These results built on previous findings obtained in
large cohorts of lymphoma samples describing mutations in
NOTCH pathway as a recurrent defect in DLBCL (83, 136–
138). Although belonging to this lymphoma category, RS is
considered a distinct subset of DLBCL, as it evolves from a pre-
existing CLL undergoing a transformation into an aggressive
lymphoma in the 10–12% of cases (123, 139). Analysis of
IGH rearrangements indicate whether RS is clonally related or
unrelated to CLL, thus if it derives from the same B cell clone
or if it arises as a secondary independent neoplasia (140). This
distinction is clinically relevant as clonally-related RS patients
are characterized by a poorer outcome, with no response to
standard therapy and with a shorter overall survival compared to
clonally unrelated samples (140–142). Whole exome sequencing
(WES) and copy-number analyses indicate that inactivation of
the TP53 tumor suppressor gene and/or 17p13 deletion represent
the most common genetic lesion, observed in ∼60% of patients,
while disruption of CDKN2A/B, a cell cycle regulator, is observed
in about 30% of cases (140, 143, 144). Other frequent genetic
lesions are represented by NOTCH1 and MYC activating events,
present in∼30% of RS cases (62, 140), and aremutually exclusive,
consistent with the hypothesis that NOTCH1 is a transcriptional
activator ofMYC (145). Mutations reported forNOTCH1mainly
affect the PEST domain, with the P2514fs∗4 truncating mutation
being the most frequent. This event results in the constitutive
activation of the pathway as inferred by the presence of the NICD
protein and high expression levels ofNOTCH1 target genes (146).
However, additional functional studies are needed to understand
whether this pathway plays a key role as a transforming event
fromCLL to RS or if it simply contributes to RS aggressiveness. In
addition, a combination of germline genetic characteristics, such
as polymorphisms in BCL2, LRP4 (147) and CD38 (148) genes,
as well as biological features of CLL cells, including unmutated
IGVH genes, Zap-70 and CD49d expression, represent risk
factors for disease development (149).
Marginal Zone Lymphoma (MZL)
MZLs, accounting for 5–17% of all non-Hodgkin’s lymphomas,
derive from B cells of the “marginal zone,” the external part of
the secondary lymphoid follicles. The MZ is more evident in the
lymphatic tissues continuously exposed to external antigens, such
as the mesenteric lymph nodes, the mucosa-associated lymphoid
tissues (MALT), and the spleen. MZ B cells act as innate-like
lymphocytes able to mount rapid antibody responses mostly to
T cell-independent antigens (150).
There are three different MZL entities with specific diagnostic
criteria, clinical behavior, and therapeutic implications: the extra-
nodal MZL of mucosa-associated lymphoid tissue (MALT) type
(MALT lymphoma), the splenic MZL (SMZL), and the nodal
MZL (NMZL) (151).
Despite specific alterations peculiar of each subtype, there are
genetic lesions and deregulated pathways that are shared (108,
152, 153). Trisomies of chromosomes 3 and 18 and deletion at
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6q23 are frequent events in allMZLs, as well as somaticmutations
of genes coding for proteins involved in chromatin remodeling
(114, 154–156). NF-kB andNOTCH are among the pathways that
are recurrently mutated in MZLs, (114, 155, 157–160).
MALT lymphoma is the most commonMZL type, accounting
for 5–8% of all B cell lymphomas (161). It arises from lymphoid
populations that are induced by chronic inflammation in extra-
nodal sites. The most frequently affected organ is the stomach,
with MALT lymphomas associated to chronic gastritis (162).
Beside infections, chronic inflammations caused by autoimmune
diseases are risk factors for the development of MALT lymphoma
(163). Using targeted sequencing approaches, mutation in
NOTCH1 (8%) and NOTCH2 (8%) genes have been recently
reported (154). Most of the aberrations are frameshift indels
and non-sense mutations, clustering in the C-terminal portion
of the molecule and specifically in the TAD and PEST domains,
in line with mutations and functional effects observed in CLL,
MCL, and SMZL. A similar pattern of mutations inNOTCH2 has
been identified through WES/whole-genome sequencing (WGS)
studies in SMZL and NMZL, with percentages varying from 10 to
25% in SMZL and∼25% in NMZL (164).
SMZL is a neoplasm of mature B cells that involves spleen,
BM, and PB. Within the spleen, tumor cells are represented by
small lymphocytes that occupy the MZ surrounding germinal
centers and infiltrate the red pulp (123). In SMZL, mutations
of NOTCH2, together with genes encoding NOTCH signaling
pathway components, represent the most recurrent genetic
lesions, remarking upon deregulated proliferation and migration
as the most affected pathways (114, 165–168). As for MALT
lymphomas, most of the identified alterations are frameshift or
non-sense mutations clustering within the hotspot region in
exon 34, affecting the PEST domain and increasing NOTCH2
activation (114, 169, 170). The 2-bp deletion (p.P2515fs∗4) in
NOTCH1, recurrent in CLL (61, 62, 171) and MCL (93), is
observed in a minor percentage of SMZL (∼5%), (114, 169, 172–
174). Furthermore, mutations in SPEN and DTX1 are reported
in a small percentage (5%) of SMZL cases (114). The former
plays a role in restraining NOTCH signaling through a physical
interaction with and consequent repression of the transcription
factor RBPJk (165, 175, 176). In physiological conditions, SPEN
is as a negative regulator of B lymphocyte differentiation into MZ
B cells counteracting the activity of NOTCH (165). Mutations
truncate SPEN C-terminal domain, which is involved in the
interaction with RBPJk and is critical for NOTCH signaling
activation. DTX1 is highly expressed in MZ B cells and may
be relevant for the late steps of B lymphocyte differentiation
(36, 177). It encodes a RING finger ubiquitin ligase that binds
NOTCH family members, modulating their signaling activity. In
SMZL, mutations map within two distinct functional domains of
DTX1, involved in protein interactions (114). Of note, mutations
in genes encoding NOTCH signaling components appear to be
largely mutually exclusive with an overall rate of mutations of the
pathway in SMZL of∼32%.
NMZL is a rare and indolent B cell tumor that differs from
SMZL in terms of pattern of dissemination, being primarily a
nodal B cell cancer without clinical evidence of extranodal or
splenic disease (123, 178). In general, the mutational profile of
NMZL is quite similar to that of SMZL, as revealed by WES
studies (179). Specifically, NOTCH signaling pathway appears to
be mutated mainly in NOTCH2 (20%), SPEN (11%), and RBPJL
(6%) (179).
Multiple Myeloma (MM)
In the last decade, several studies have highlighted a role for
the NOTCH pathway in MM, a tumor characterized by the
proliferation of BM post-GC plasma cells, with release of
monoclonal antibodies in blood (180). From the pathological
standpoint, MM is characterized by profound genomic
instability, epigenetic alterations and strongly dependent on the
interaction with the microenvironment (181–184). Indeed, MM
cells localization in the BM milieu allows direct interactions
between tumor and non-tumor cells residing in the BM,
via adhesion molecules and soluble factors, which promote
neoplastic cell growth, survival, bone disease, acquisition of drug
resistance, and consequent disease relapse. Cumulative evidence
indicates a key role of NOTCH signaling in MM onset and
progression (185–188).
Unlike other NOTCH-related malignancies, where the
majority of patients carry gain-of-function mutations in pathway
members, in MM cells NOTCH signaling is aberrantly activated
due to increased expression of both receptors and ligands
(185, 186). In physiological conditions, hematopoietic stem
cells express NOTCH receptors receiving signals from ligands
expressed by BM stromal cells. This mechanism contributes
to stem cell renewal, survival and differentiation. In MM, this
interplay is hijacked by tumor cells to enhance their proliferative
rate and escape from therapy (189). Moreover, experimental
evidence indicates that NOTCH signaling directly regulates
the expression and function of CXCR4, thereby controlling
trafficking of MM cells toward BM niches, a mechanism similar
to that described in CLL (190).
Several independent studies report the overexpression of
NOTCH1 and 2 and the two ligands Jagged1 and Jagged2
by MM cells (185, 186, 191, 192) during disease progression.
Indeed, increased NOTCH1 and Jagged1 expression parallels
the transition from monoclonal gammopathy of undertermined
significance (MGUS) to MM (186), while NOTCH2 expression is
increased in more aggressive subsets of patients, carrying specific
translocations (193). Of note, most of the genes belonging to the
NOTCH signaling pathway are located on chromosomes found
to be numerically altered in selected subtypes of MM (9).
Notably, the overexpression of the “NOTCH network” also
results in the activation of NOTCH signaling in surrounding
stromal cells, contributing tomyeloma cell proliferation, survival,
and migration, as well as to bone disease and intrinsic and
acquired pharmacological resistance. This “backward signaling”
occurs as a consequence of activation of NOTCH receptors
on BM stromal cells by ligands expressed by MM cells. This
interaction results in a NOTCH-mediated upregulation of IL-
6 secretion by BM stromal cells, one of the most important
growth and survival factors for MM cells (188). The existence
of a bidirectional NOTCH signaling offers novel hints in the
study of B cell malignancies, and opens new perspectives in the
therapeutic scenario.
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IS NOTCH DRUGGABLE IN B CELL
MALIGNANCIES?
Independently of the mutational status, NOTCH signaling
activation is tightly regulated at multiple steps, thereby providing
different strategies to therapeutically target this pathway. In
a top-down view, we can envisage at least three levels
of intervention: (i) in the extracellular space, interrupting
receptor/ligand interactions with specific blocking antibodies;
(ii) at the membrane level, preventing the enzymatic cleavages
critical for NOTCH activation; and (iii) inside the cells, exploiting
selective inhibitors of the “NOTCH interactome.”
Given the widespread involvement of this molecular family
in cancer, the NOTCH “drug market” has rapidly grown with
the development of antibodies or inhibitors, tested in multiple
clinical trials, particularly in the context of solid tumors and
T-ALL, with only studies in B cell malignancies (9, 194).
Initial results using γ-secretase inhibitors (GSI) demonstrated
excessive toxicity, particularly at the gastrointestinal levels,
mainly due on one side to off-target effects and on the other
side to the simultaneous targeting of all NOTCH isoforms,
expressed on several tissues, thus interfering also with the
physiological role of this pathway. The introduction of different
schemes of administration, the combination with steroids and
the design of more selective inhibitors and drugs have partly
overcome these side effects, attaining promising therapeutic
responses. In line with the aim of increasing treatment
specificity while minimizing toxicity, monoclonal antibodies,
specifically binding single members of the NOTCH family,
were designed as an alternative approach (195). However,
these reagents have not yet reached clinical trials in B-cell
malignancies.
An alternative to GSI approaches is immunotherapy,
based on the use of blocking antibodies against NOTCH,
Delta/Jagged ligands or other extracellular components
involved in the NOTCH signaling cascade. Since these drugs
affect selectively a NOTCH family member or ligand, they
could potentially show fewer side effects compared to GSI
(195–198).
Even if limited results have been obtained in clinical trials
for B cell neoplasms, promising evidence for the use of these
drugs is coming from in vitro and ex-vivo data obtained in MCL
(93) and MM (84). Treatment with GSI resulted in decreased
proliferation and increased apoptosis of MCL cell lines, with
a concomitant modulation of a selected set of genes strictly
dependent on NOTCH. These inhibitors proved to be effective
in MM acting directly on tumor cells by enhancing apoptosis
but also preventing the BM stroma-mediated protection of MM
cells from drug-induced apoptosis. Furthermore, GSI is able to
enhance the cytotoxicity induced by selective chemotherapeutic
agents, including doxorubicine (85).
Similar effects of GSI, used alone or in combination with
fludarabine, were obtained in the high-risk CLL subset of patients
carrying a mutated NOTCH1. These cells proved to be sensitive
to PF-03084014, a non-competitive and reversible GSI, with
inhibition of the constitutive activation of the pathway and
modulation of apoptosis, as well as migration of leukemic cells
(69). Further evidence sustaining a combination strategy to target
CLL cells was recently obtained by Secchiero and colleagues who
reported the ability of GSI to enhance the anti-leukemic activity
of ibrutinib, independently of the mutational status of NOTCH1
(199).
Considering that, in hematological B cell malignancies,
deregulated NOTCH signaling is ancillary to driver aberrant
pathways, a combined therapeutic approach may represent a
successful way to target tumor cells.
CONCLUDING REMARKS
To bear witness of the importance of NOTCH in normal B-
cell ontogenesis, mutations in genes belonging to this pathway
are invariably found in all mature B cell malignancies. In
some instances, the mutational burden insisting on the pathway
reaches one third or more of patients, as is the case for MZL
or RS. Overall, the emerging picture is that NOTCH signaling
is finely tuned in cell- and microenvironment-specific ways. In
B cell malignancies, it works primarily as an oncogene, even
though functional studies on the mechanisms and consequences
of NOTCH signaling are only starting now. Likely, they will allow
to improve its therapeutic targeting, also through the design and
validation of more selective drugs.
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